Calvert Research Competitors

IITRI was founded in 1936 as the research arm of the Illinois Institute of Technology (IIT). IITRI operates as an independent, not-for-profit preclinical contract research organization and research institute. Current facilities include over 110,000 square feet of laboratory space in one location in Chicago, with all functions under one roof. Areas of specialty include preclinical safety and toxicology, inhalation toxicology, biodefense and infectious disease studies, and bioanalytical services. In addition, we have extensive experience evaluating the efficacy and preclinical safety of cancer therapeutics and are the largest commercial CRO contractor to the National Cancer Institute (NCI). We provide preclinical safety and toxicology testing services to sponsors from the pharmaceutical, biotechnology, consumer products, and chemical industries, as well as to the U.S. Government for rodent, non-rodent and non-human primate (NHP) studies. Our researchers provide specialized expertise in infectious disease, IND-enabling toxicology programs, inhalation toxicology for chemicals or pharmaceuticals, and cancer biology/immunology. As a mid-size CRO, we provide personalized attention and rapid study start dates. Our PhD/DABT study directors are available for consultation and updates throughout the duration of the study, and we offer flexible study design and adjustments. We look forward to discussing your study with you!

Collaborating on all therapeutic modalities, Resolian fuses expertise from Alliance Pharma and Drug Development Solutions to provide world-class scientific solutions. We are an ever-expanding global team of experts, resolute in our goal to offer an accessible, enhanced customer experience through a personalized approach and proactive management. With Resolian Bioanalytics, our vast expertise, from next-generation biologics to cell and gene therapy, allows us to find solutions to the most challenging bioanalytical methods and assays. Resolian Analytical Sciences builds on two decades of experience solving the most complex challenges in testing raw materials, formulated products, packaging and medical devices for trace impurities, contamination, degradation and quality control. Learn more about us at resolian.com.

Melior Discovery is a preclinical in vivo pharmacology contract research organization (CRO) headquartered in Exton, Pennsylvania. Founded in 2005, Melior specializes in in vivo phenotypic screening, drug repositioning (repurposing), and efficacy evaluation for global pharmaceutical and biotechnology companies. At the core of our capabilities is theraTRACE®, a proprietary high-throughput phenotypic screening platform utilizing multiplexed in vivo disease models. This unique platform allows drug discovery teams and developers to evaluate compounds across up to 40 distinct animal models of human disease simultaneously, spanning 14 therapeutic areas to uncover unexpected indications and de-risk pipeline decisions. Core Preclinical Services & Platforms: theraTRACE®: Multiplexed phenotypic screening for indications discovery. immuno-theraTRACE™: Oncology-focused screening for immune-modulating agents and tumor models. opioidTRACE®: Analgesic-focused platform evaluating pain pathways and abuse liability. Custom In Vivo Models: Over 150 validated rat and mouse models covering CNS, metabolic, inflammation, dermatology, and GI disorders. Supporting Services: Pharmacokinetic (PK) evaluations, bioanalytical services, and specialized surgery/implants (e.g., orthotopic intracranial). Since 2005, Melior has served hundreds of biopharma partners, from venture-backed startups to multinational pharmaceutical firms. Melior was recognized as CRO of the Year by Life Sciences Review and named a Top 20 CRO by Pharma Tech Outlook.